Global Blood Cancer Cases Projected to Surge 70 Percent by 2050 as China and US Face Divergent Trends

A new analysis of global data highlights the rising burden of leukemia and lymphoma, with China and the US facing unique risks from aging and lifestyle factors.

By: AXL Media

Published: Mar 25, 2026, 6:52 AM EDT

Source: Information for this report was sourced from Chinese Medical Journal

The Rising Global Toll of Hematological Malignancies

The landscape of blood-related cancers is undergoing a profound shift, with new data from GLOBOCAN and the GBD Study 2021 highlighting a significant public health crisis. In 2022 alone, hematological malignancies, which include leukemia and various lymphomas, represented approximately 7% of all cancer deaths worldwide. According to the research team led by Professor Xiao-Jun Huang, the sheer volume of new cases is a testament to the growing strain on global healthcare infrastructure, as these diseases now affect over 1.3 million individuals annually. This rising tide is particularly evident in non-Hodgkin lymphoma and multiple myeloma, both of which have seen steady increases in incidence rates over the past thirty years.

Divergent Epidemiological Profiles in China and the United States

When comparing the world’s two largest economies, researchers identified starkly different disease patterns that reflect broader socio-economic and diagnostic realities. In the United States, non-Hodgkin lymphoma stands as the most prevalent subtype, whereas leukemia remains the leading blood cancer diagnosis within the Chinese population. According to the study, the US currently maintains higher age-standardized incidence rates, a factor the authors attribute to more comprehensive screening programs, a higher Human Development Index, and an aging population. However, while the US is seeing a downward trend in incidence across all subtypes, China is experiencing a rise in leukemia, myeloma, and lymphoma cases as its diagnostic capabilities and cancer registration systems continue to mature.

The Heavy Burden on Aging Populations

Age remains the most significant non-modifiable risk factor, with over 70% of all blood cancer deaths occurring in patients over the age of 50. The data indicates that the risk escalates dramatically in the elderly, with those aged 85 and older facing the highest incidence rates recorded. According to Professor Xiang-Yu Zhao, Hodgkin lymphoma presents a unique challenge due to its bimodal distribution, which creates two distinct peaks of vulnerability: one in young adults and another in the elderly. This age-related clustering suggests that public health strategies must be specifically tailored to different life stages, balancing the needs of a younger workforce with the intensive care requireme...